See article

Asking the Right Questions: Staying Ahead of the CTR and MDR with the EU Legal Representative

The EU legal representative plays a unique role in the life sciences industry and requires a distinctive skill set – with a background in regulatory affairs and quality assurance, but from inside the good clinical practice (GCP) sphere. Now, with the added complexity of the Clinical Trials Regulation and the Medical Devices Regulation, the role […]

See article

The QA to the Sponsor’s QA: Why the Legal Representative Should be Separate from the CRO

The role of the legal representative for clinical studies – both in pharmaceuticals and now in medical devices under the EU Medical Devices Regulation (MDR) – might be described as quality assurance of the sponsor’s QA role. In future, under the new EU Clinical Trials Regulation (CTR) and MDR, the legal representative will be responsible […]

See article

Why “Ensuring” the Sponsor’s Compliance is Not the Right Role for CROs

The Medical Devices Regulation will bring massive and rapid change to the industry. Not only must companies adjust to new clinical investigation requirements, but they will suddenly find themselves in need of a number of new experts. Medical device companies wanting to run clinical investigations of their products in Europe will need a qualified person […]

See article

This Changes Everything: MDR and the Role of the EU Legal Representative

The medical devices industry has changed dramatically in recent years. Historically, medical devices had more in common with product manufacturing industries such as aviation, which meant testing and standards were very engineering focussed: Is the product built robustly? Are the materials adequate for their intended purpose? Will the product and materials last? While those standards […]

See article

Getting Ready for the Clinical Trial Regulation

Blog series: Maintaining Regulatory Momentum in the Covid-19 era: It’s been a difficult year for many biopharma companies and perhaps even more so for clinical research organisations, with Covid-19 forcing the postponement or even cancellation of many if not most clinical trials.  It is however important to keep a finger on the pulse of the […]

See article

Medical Devices Back in the Spotlight

Blog series: Maintaining Regulatory Momentum in the Covid-19 era: Preparation for the new regulations  The global disruption caused by the pandemic meant regulatory plans for 2020 needed to be delayed to give the life sciences industry and authorities breathing room. However, it is important to keep up to date with imminent regulatory changes that will […]

See article

Data protection to take centre stage in 2021

Blog series: Maintaining Regulatory Momentum in the Covid-19 era: In early December, the EMA announced that it had been hit by a cyber-attack and that documents related to the Pfizer-BioNTech Covid-19 vaccines had been accessed. The agency issued a brief announcement after the attack to say a full investigation had been launched but provided no […]

See article

Orphan Unknowns: What the MHRA Guidance Will Mean After Brexit

Blog series: Maintaining Regulatory Momentum in the Covid-19 era: Developers of orphan drug products face some important changes with the approval process in the UK after Brexit. To help companies prepare, the MHRA published new guidance: “How the MHRA will manage orphan medicinal products from 1 January 2021 in Great Britain (GB)”. While most of […]

See article

Why Transparency in reporting negative results is key for public trust

A recent perspective piece published in the New England Journal of Medicine highlights an issue that I have long felt reflects poorly on the industry, and that is public mistrust in ’Big Pharma’. This issue has come to the fore with the race to bring a Covid-19 vaccine to market. While the authors talk about […]

See article

Start with the end in mind: how to build a solid Target Product Profile

Start with the end in mind. That is one of the most important considerations for companies seeking to conduct clinical trials in the global market. A common mistake made by smaller biotech companies — and even older companies that have not done a lot of R&D in recent years — is to think only of […]

See article

Just how patient-centric is R&D? The desperate need for accessible rare disease data

There is much talk today about patient-centricity in the clinical trials, from discussions about how to ease the burden for patients, to how to empower and engage patients. But to my mind a central aspect of patient centricity that is poorly addressed is how patients and advocacy groups get better access to medical research, or […]

See article

Why the Hiatus to Clinical Trials Amid Coronavirus is a Chance to Improve Processes

It’s hard to consider a bright side to the current coronavirus pandemic the world finds itself in, but the delays and temporary suspension of many clinical trials do present an opportunity to step back and address gaps in many trial processes. The question, then, is how can you use this time efficiently and effectively to […]

See article

Keeping your EU submissions moving with our Regulatory-on-Call service

Despite having talented teams, small companies are forced to work with limited resources and access to specific expertise. They often lack the resources and experience in navigating specific regulations, the nuances of working in different countries and have limited time to spend on regulatory intelligence. Working with a regulatory expert who is familiar with your […]

See article

Balancing risk and reward: The cost of providing legal representative support

When regulations change there are always a few aspects where the careful reader finds themselves asking “did they really mean that?”. In that vein there is a somewhat ominous clause in the new Clinical Trial Regulation, at least from the point of view of the legal representative. Article 74 of the regulation states: “Such legal […]

See article

Quis custodiet ipsos custodes: Who will hold the sponsors to account?

The long-awaited new Clinical Trials Regulation looks set to be introduced in 2020. Initially adopted in 2014 and due to go into force soon afterwards, it was held up by technical difficulties with the database, which is necessary to underpin the new environment. The latest testing suggests these problems have been resolved. The new regulation […]

See article

Silver Linings: How Regulatory Learnings from the Covid-19 Pandemic Could Bring Future Improvements to Research

I’m a huge believer that even in the very worst of circumstances, there is always a silver lining (or two) to be found. We  have already seen some of these playing out during this pandemic in the many ways people are coming together to spread hope and goodwill between and across communities. One positive that […]

See article

Two in one go: Don’t shy away from joint consultation with EMA and HTAs

It’s understandable that companies tend to be focused first on getting their products approved. But that’s just part of the battle. The other part is getting your products paid for. In July 2017, EMA began offering consultations in parallel with the European Network for Health Technology Assessment (EUnetHTA). The objective is to ensure that you […]

See article

Can you Meet GMP Requirements? The Importance of Preparing Manufacturing Data

In drug development, it’s often the area you least expect that causes the most problems. In my experience, one of the biggest hold-ups to completing regulatory submission dossiers relates to manufacturing, not the safety and efficacy data. The information needed for the Investigational Medicinal Product Dossier (IMPD) or CTD Module 3 (M3) — stability testing, […]

See article

Lost in translation: Manoeuvring through the complex world of regulatory language

The regulatory process is complex and can be very difficult to navigate. It’s not just about gathering data and meeting milestones, but also about understanding the regulatory language. Often,  young biopharma companies come to me after completing a scientific advice procedure with the regulators and are under the impression that the agency in question have […]

See article

Keeping everyone in the loop: why all stakeholders need to hear the patient voice

In a previous blog post (Linked here), I raised the issue of patient-centricity and my concern that it is being used more as a marketing tool than a way to build truly patient-centric products. To shift that thinking, there needs to be broad commitment to bringing patients into the fold at every stage of the […]

See article

Dream big but remain focused: Why lofty goals can derail the development process

Start-ups and emerging biotech companies often start out with lofty goals about what their products can do. That’s very noble but it’s also an easy way to run out of money halfway through the development process. While it’s good to have long-term goals, success depends on developing a well-defined target product profile (TPP). Start with […]

See article

Less talk more action: Building real patient-centricity from trial design

Patient-engagement or patient-centricity is now widely spoken about, but it’s rarely brought into the process of product development early on. As a regulatory consultant, my role is to fulfil the objectives of our clients as I help them navigate the clinical trial approvals process and I strongly believe that this would be a good point […]

See article

Speaking up: How a conversation with the regulators can set the stage for success

There is very often a them-and-us mentality when it comes to how biotech companies think about the regulators. New companies, in particular, tend to view what is said by the regulators as prescriptive and are afraid to speak to them or get the scientific advice that is available. However, if they did take time to […]

See article

IDEA Regulatory Ensures Continuity for Clients Amid Coronavirus

The global coronavirus pandemic, or COVID-19, has brought about both a health crisis as well as personal and business uncertainty. Yet bringing new life saving and life changing products to market remains a pressing priority. Patients are waiting for cures and their needs cannot be postponed. As a leader in providing regulatory affairs expertise and […]